Hormone replacement therapy in healthy postmenopausal women: A randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors

Journal of Internal Medicine

Volumn 249, Issue 3, 2001, Pages 237-246

  Gottsater A ^a   Rendell, M ^a   Hulthen U L ^a   Berntorp, E ^a   Mattiasson, I ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Coagulation; Fibrinolysis; Menopause; Oestrogen

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; ESTRADIOL; FIBRINOGEN; FIBRINOLYTIC FACTOR; MEDROXYPROGESTERONE ACETATE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AMENORRHEA; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOGENESIS; TREATMENT OUTCOME;

BLOOD COAGULATION; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FIBRINOLYSIS; HUMANS; MENOPAUSE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 0035002657     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00797.x     Document Type: Article

References (36)

1. Postmenopausal hormone therapy and mortality
2. Disparate cardiovascular findings in men and women with essential hypertension
3. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status
4. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy
5. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
6. Prospective study of exogenous hormones and risk of pulmonary embolism in women
7. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens
8. Risk of venous thromboembolism in users of hormone replacement therapy
9. Coagulation activation following estrogen administration to postmenopausal women
10. Haemostatic variables and menopausal status: Influence of hormone replacement therapy
11. Thrombosis and hormone replacement therapy in postmenopausal women
12. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
13. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study
14. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis
15. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
16. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial
17. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study
18. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease. Results from the estrogen in women with atherosclerosis study
19. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study
20. Effect of estrogen-progestin hormonal replacement therapy on plasma anti-thrombin III of postmenopausal women
21. Hormone replacement therapy in healthy postmenopausal women. Effects on intraplatelet cyclic guano-sine monophosphate, plasma endothelin-1 and neopterin
22. Von Willebrand factor and its relevance to cardiovascular disease
23. Von Wille-brand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma
24. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
25. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
26. Changes in plasma levels of vitamin K-dependent proteins C and S of C4b-binding protein during pregnancy and oral contraception
27. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review
28. Activated protein C resistance as a basis for venous thrombosis
29. Short and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women
30. Estrogen replacement therapy and coagulation: Relationship to lipid and lipoprotein changes
31. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: A placebo-controlled study with nomegestrol acetate and estradiol
32. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
33. Influence of hormone replacement therapy (17 beta-OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin-antithrombin III complex in postmenopausal woman
34. Sensitivity to activated protein C; influence of oral contraceptives and sex
35. How progestins compromise the cardioprotective effects of estrogens